{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T02:04:30Z","timestamp":1776132270242,"version":"3.50.1"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012505","name":"Hebei Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015285","name":"Hebei Province Medical Science Research Key Project","doi-asserted-by":"publisher","award":["20260489"],"award-info":[{"award-number":["20260489"]}],"id":[{"id":"10.13039\/501100015285","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bioorg.2026.109744","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:59:54Z","timestamp":1773421194000},"page":"109744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Synthesis and evaluation of Urolithins derivatives as anticancer agents for hepatocellular carcinoma: In vitro, molecular docking, and dynamics simulations"],"prefix":"10.1016","volume":"174","author":[{"given":"Jiahao","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liman","family":"Huo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jintuo","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luya","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.109744_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2026.109744_bb0010","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","article-title":"Global, regional and national burden of primary liver cancer by subtype","volume":"161","author":"Rumgay","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.109744_bb0015","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s10555-023-10084-4","article-title":"Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers","volume":"42","author":"Wang","year":"2023","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bioorg.2026.109744_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2025.116914","article-title":"Elucidation of the potential mechanism of euphorbiae Pekinensis Radix and Glycyrrhizae Radix for the remission of ascites in hepatocellular carcinoma using a comprehensive strategy based on chinmedomics, pharmacology, and biopharmaceutics","volume":"263","author":"Liu","year":"2025","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.bioorg.2026.109744_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117178","article-title":"Ellagic acid mediated pyroptosis in hepatocellular carcinoma via the ESR1\/G6PD pathway","volume":"241","author":"Wang","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109744_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2019.152921","article-title":"Ellagic acid synergistically potentiates inhibitory activities of chemotherapeutic agents to human hepatocellular carcinoma","volume":"59","author":"Zhong","year":"2019","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bioorg.2026.109744_bb0035","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2026.109744_bb0040","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.sjbs.2014.03.004","article-title":"The protective role of ellagitannins flavonoids pretreatment against N-nitrosodiethylamine induced-hepatocellular carcinoma","volume":"21","author":"Hussein","year":"2014","journal-title":"Saudi J Biol Sci"},{"key":"10.1016\/j.bioorg.2026.109744_bb0045","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.2174\/1871520618666180604085612","article-title":"An overview of natural plant products in the treatment of hepatocellular carcinoma","volume":"18","author":"Rawat","year":"2018","journal-title":"Anticancer Agents Med Chem."},{"key":"10.1016\/j.bioorg.2026.109744_bb0050","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2174\/0113894501312571240920070441","article-title":"A review on Nanotechnologically derived Phytomedicines for the treatment of hepatocellular carcinoma: recent advances in molecular mechanism and drug targeting","volume":"26","author":"Sahu","year":"2025","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.bioorg.2026.109744_bb0055","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular Carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.109744_bb0060","article-title":"Ellagic acid inhibits tumor growth and potentiates the therapeutic efficacy of sorafenib in hepatocellular carcinoma","volume":"10","author":"Tan","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.bioorg.2026.109744_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2025.156576","article-title":"Metabolism profiles of tannins in Phyllanthus emblica L. and its immunotherapeutic potential against hepatocellular carcinoma by re-educating tumor microenvironment","volume":"140","author":"Chang","year":"2025","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bioorg.2026.109744_bb0070","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11130-025-01313-y","article-title":"Unveiling the cytotoxic and NO inhibitory potential of Heliotropium dolosum extracts from Turkiye: A first insight into its phenolic profile","volume":"80","author":"Ozay","year":"2025","journal-title":"Plant Foods Hum. Nutr."},{"key":"10.1016\/j.bioorg.2026.109744_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2025.120492","article-title":"Therapeutic effects of the n-butanol extract of Potentilla freyniana Bornm. In hepatocellular carcinoma cells","volume":"354","author":"Wang","year":"2026","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.bioorg.2026.109744_bb0080","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.molmed.2021.04.009","article-title":"Impact of the natural compound Urolithin A on health, disease, and aging","volume":"27","author":"D'Amico","year":"2021","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bioorg.2026.109744_bb0085","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1080\/10408398.2022.2036693","article-title":"Ellagic acid and intestinal microflora metabolite urolithin A: A review on its sources, metabolic distribution, health benefits, and biotransformation","volume":"63","author":"Zhang","year":"2023","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"10.1016\/j.bioorg.2026.109744_bb0090","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s13668-025-00645-0","article-title":"Urolithin as a metabolite of Ellagitannins and Ellagic acid from fruits and nuts produced by the gut microbiota: its role on non-communicable diseases","volume":"14","author":"Ribeiro","year":"2025","journal-title":"Curr Nutr Rep"},{"key":"10.1016\/j.bioorg.2026.109744_bb0095","doi-asserted-by":"crossref","first-page":"17273","DOI":"10.1002\/jcb.28989","article-title":"Urolithin B suppresses tumor growth in hepatocellular carcinoma through inducing the inactivation of Wnt\/beta-catenin signaling","volume":"120","author":"Lv","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bioorg.2026.109744_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0258998","article-title":"1,8 cineole and Ellagic acid inhibit hepatocarcinogenesis via upregulation of MiR-122 and suppression of TGF-beta1, FSCN1, vimentin, VEGF, and MMP-9","volume":"17","author":"Abdallah","year":"2022","journal-title":"PloS One"},{"key":"10.1016\/j.bioorg.2026.109744_bb0105","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.tiv.2015.04.008","article-title":"In vitro antiproliferative and antioxidant effects of urolithin A, the colonic metabolite of ellagic acid, on hepatocellular carcinomas HepG2 cells","volume":"29","author":"Wang","year":"2015","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.bioorg.2026.109744_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2021.129911","article-title":"Transcriptome analysis of signaling pathways targeted by Ellagic acid in hepatocellular carcinoma cells","volume":"1865","author":"Qiu","year":"2021","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.bioorg.2026.109744_bb0115","first-page":"387","article-title":"Ellagic acid holds promise against hepatocellular carcinoma in an experimental model: mechanisms of action","volume":"19","author":"Zaazaa","year":"2018","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.bioorg.2026.109744_bb0120","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431x20187220","article-title":"Antiproliferative effect of urolithin A, the ellagic acid-derived colonic metabolite, on hepatocellular carcinoma HepG2.2.15 cells by targeting Lin28a\/let-7a axis","volume":"51","author":"Qiu","year":"2018","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.bioorg.2026.109744_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15194891","article-title":"Modulation of the tumor microenvironment by Ellagic acid in rat model for hepatocellular carcinoma: A potential target against hepatic Cancer stem cells","volume":"15","author":"Ramadan","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2026.109744_bb0130","article-title":"Recent advances and perspectives on the health benefits of Urolithin B, A bioactive natural product derived from Ellagitannins","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109744_bb0135","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2021.647582","article-title":"Urolithins: the gut based polyphenol metabolites of Ellagitannins in Cancer prevention, a review","volume":"8","author":"Al-Harbi","year":"2021","journal-title":"Front. Nutr."},{"key":"10.1016\/j.bioorg.2026.109744_bb0140","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1021\/jf0527403","article-title":"Urolithins, ellagic acid-derived metabolites produced by human colonic microflora, exhibit estrogenic and antiestrogenic activities","volume":"54","author":"Larrosa","year":"2006","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.bioorg.2026.109744_bb0145","doi-asserted-by":"crossref","first-page":"10636","DOI":"10.1021\/jf902716r","article-title":"Effects of pomegranate chemical constituents\/intestinal microbial metabolites on CYP1B1 in 22Rv1 prostate cancer cells","volume":"57","author":"Kasimsetty","year":"2009","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.bioorg.2026.109744_bb0150","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jchromb.2015.03.024","article-title":"Preparative isolation and purification of urolithins from the intestinal metabolites of pomegranate ellagitannins by high-speed counter-current chromatography","volume":"990","author":"Zhao","year":"2015","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.bioorg.2026.109744_bb0155","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1039\/C5FO00120J","article-title":"The ellagic acid-derived gut microbiota metabolite, urolithin A, potentiates the anticancer effects of 5-fluorouracil chemotherapy on human colon cancer cells","volume":"6","author":"Gonzalez-Sarrias","year":"2015","journal-title":"Food Funct."},{"key":"10.1016\/j.bioorg.2026.109744_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2022.101846","article-title":"Urolithins increased anticancer effects of chemical drugs, ionizing radiation and hyperthermia on human esophageal carcinoma cells in vitro","volume":"77","author":"Mirzaei","year":"2022","journal-title":"Tissue Cell"},{"key":"10.1016\/j.bioorg.2026.109744_bb0165","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.fct.2019.04.031","article-title":"Protective effect of urolithin a on cisplatin-induced nephrotoxicity in mice via modulation of inflammation and oxidative stress","volume":"129","author":"Jing","year":"2019","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.bioorg.2026.109744_bb0170","article-title":"Enhancing the efficacy of radiotherapy in gastric adenocarcinoma cells by gut microbiota metabolites: implications for Urolithin combination therapy","volume":"19","author":"Ahmadi","year":"2024","journal-title":"Nat. Prod. Commun."},{"key":"10.1016\/j.bioorg.2026.109744_bb0175","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1158\/2767-9764.CRC-24-0022","article-title":"Urolithin-A promotes CD8+ T cell-mediated Cancer Immunosurveillance via FOXO1 activation","volume":"4","author":"Ginefra","year":"2024","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.bioorg.2026.109744_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.109324","article-title":"Ellagic acid derivatives as potential inhibitors of melanoma cell metastasis: insights into MMP-related mechanisms","volume":"168","author":"Qatran","year":"2026","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109744_bb0185","doi-asserted-by":"crossref","first-page":"25941","DOI":"10.1038\/s41598-025-11804-2","article-title":"Urolithin A suppressed osteosarcoma cell migration and invasion via targeting MMPs and AKT1","volume":"15","author":"Ahmadi","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.109744_bb0190","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40168-025-02045-6","article-title":"Microbiota-derived urolithin A in monoclonal gammopathies and multiple myeloma therapy","volume":"13","author":"Rodriguez-Garcia","year":"2025","journal-title":"Microbiome"},{"key":"10.1016\/j.bioorg.2026.109744_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/nu15234854","article-title":"Inhibitory effects of Urolithins, bioactive gut metabolites from natural polyphenols, against glioblastoma progression","volume":"15","author":"Shen","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.bioorg.2026.109744_bb0200","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1080\/01635581.2020.1829653","article-title":"Synergistic effects of Ellagic acid and Sorafenib on hepatocytes and mitochondria isolated from a hepatocellular carcinoma rat model","volume":"73","author":"Salimi","year":"2021","journal-title":"Nutr. Cancer"},{"key":"10.1016\/j.bioorg.2026.109744_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100701","article-title":"The potential mechanism of Chebulae Fructus in the treatment of hepatocellular carcinoma on the basis of network pharmacology","volume":"27","author":"Jiang","year":"2022","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.bioorg.2026.109744_bb0210","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202300124","article-title":"New bioactive Dipiperazine derivatives; synthesis, molecular docking and urease inhibition study","volume":"8","author":"Saeedian Moghadam","year":"2023","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bioorg.2026.109744_bb0215","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2025.2490707","article-title":"Design, synthesis and biological evaluation of novel urolithin derivatives targeting liver cancer cells","volume":"40","author":"Tian","year":"2025","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109744_bb0220","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202000197","article-title":"Synthesis, characterization, molecular docking, and biological activities of some natural and synthetic Urolithin analogs","volume":"17","author":"Noshadi","year":"2020","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.bioorg.2026.109744_bb0225","doi-asserted-by":"crossref","first-page":"23792","DOI":"10.1038\/s41598-021-03194-y","article-title":"Design, synthesis, and biological evaluation of novel urolithins derivatives as potential phosphodiesterase II inhibitors","volume":"11","author":"Tang","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.109744_bb0230","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1053\/j.gastro.2023.01.033","article-title":"Global epidemiology and genetics of hepatocellular carcinoma","volume":"164","author":"Toh","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bioorg.2026.109744_bb0235","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ijc.32723","article-title":"International trends in hepatocellular carcinoma incidence, 1978-2012","volume":"147","author":"Petrick","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.109744_bb0240","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2026.109744_bb0245","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109744_bb0250","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.annonc.2024.03.005","article-title":"Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040","volume":"35","author":"Melero","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2026.109744_bb0255","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jep.2013.07.030","article-title":"Chinese herbal medicine-derived compounds for cancer therapy: a focus on hepatocellular carcinoma","volume":"149","author":"Hu","year":"2013","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.bioorg.2026.109744_bb0260","doi-asserted-by":"crossref","first-page":"7879","DOI":"10.1021\/acs.jmedchem.0c02026","article-title":"Marine natural products: A potential source of anti-hepatocellular carcinoma drugs","volume":"64","author":"Ren","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109744_bb0265","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1080\/13880209.2016.1214742","article-title":"Anti-hepatocellular carcinoma activity and mechanism of chemopreventive compounds: ursolic acid derivatives","volume":"54","author":"Huang","year":"2016","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.bioorg.2026.109744_bb0270","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2174\/1389557522666220516125500","article-title":"The synthesis of Urolithins and their derivatives and the modes of antitumor action","volume":"23","author":"Xu","year":"2023","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109744_bb0275","article-title":"A review of the dietary intake, bioavailability and health benefits of Ellagic acid (EA) with a primary focus on its anti-Cancer properties","volume":"15","author":"Harper","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.bioorg.2026.109744_bb0280","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mc.22746","article-title":"Metabolite of ellagitannins, urolithin A induces autophagy and inhibits metastasis in human sw620 colorectal cancer cells","volume":"57","author":"Zhao","year":"2018","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.bioorg.2026.109744_bb0285","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s12192-020-01189-8","article-title":"Urolithin A induces cell cycle arrest and apoptosis by inhibiting Bcl-2, increasing p53-p21 proteins and reactive oxygen species production in colorectal cancer cells","volume":"26","author":"El-Wetidy","year":"2021","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.bioorg.2026.109744_bb0290","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.canlet.2008.03.043","article-title":"Multitargeted therapy of cancer by ellagitannins","volume":"269","author":"Heber","year":"2008","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2026.109744_bb0295","doi-asserted-by":"crossref","unstructured":"Bang, J.; Jun, M.; Lee, S.; Moon, H.; Ro, S.W. Targeting EGFR\/PI3K\/AKT\/mTOR signaling in hepatocellular carcinoma. Pharmaceutics 2023, 15, 2130, 1.","DOI":"10.3390\/pharmaceutics15082130"},{"key":"10.1016\/j.bioorg.2026.109744_bb0300","doi-asserted-by":"crossref","unstructured":"Gao J, Huo Z, Song X, et al. EGFR mediates epithelial\u2011mesenchymal transition through the Akt\/GSK-3\u03b2\/Snail signaling pathway to promote liver cancer proliferation and migration. Oncol. Lett. 2023, 27(2), 59, doi:https:\/\/doi.org\/10.3892\/ol.2023.14192.","DOI":"10.3892\/ol.2023.14192"},{"issue":"19","key":"10.1016\/j.bioorg.2026.109744_bb0305","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910317","article-title":"Role of HSP90 in Cancer","volume":"22","author":"Birbo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bioorg.2026.109744_bb0310","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.cstres.2024.05.005","article-title":"An update on the status of HSP90 inhibitors in cancer clinical trials","volume":"29","author":"Rastogi","year":"2024","journal-title":"Cell Stress Chaperones"},{"issue":"16","key":"10.1016\/j.bioorg.2026.109744_bb0315","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1158\/1078-0432.CCR-17-3775","article-title":"\u0394Np63\u03b3\/SRC\/slug signaling Axis promotes epithelial-to-mesenchymal transition in squamous cancers","volume":"24","author":"Srivastava","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109744_bb0320","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13058-021-01462-3","article-title":"ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer","volume":"23","author":"Brett","year":"2021","journal-title":"Breast Cancer Res."},{"issue":"7","key":"10.1016\/j.bioorg.2026.109744_bb0325","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/modpathol.3800146","article-title":"Overexpression of caspase-3 in hepatocellular carcinomas","volume":"17","author":"Persad","year":"2004","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bioorg.2026.109744_bb0330","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.semcancer.2025.06.006","article-title":"Insulin resistance in cancer risk and prognosis","volume":"114","author":"Jacobo-Tovar","year":"2025","journal-title":"Semin. Cancer Biol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109744_bb0335","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/cac2.12117","article-title":"The EGFR-P38 MAPK axis up-regulates PD-L1 through miR-675-5p and down-regulates HLA-ABC via hexokinase-2 in hepatocellular carcinoma cells","volume":"41","author":"Liu","year":"2021","journal-title":"Cancer Commun. (Lond.)"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826002804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826002804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T01:39:53Z","timestamp":1776130793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826002804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":67,"alternative-id":["S0045206826002804"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109744","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and evaluation of Urolithins derivatives as anticancer agents for hepatocellular carcinoma: In vitro, molecular docking, and dynamics simulations","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109744","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109744"}}